check_circleStudy Completed

Follicular lymphoma, Non-Hodgkins-Lymphoma

Bayer Identifier:

91459

ClinicalTrials.gov Identifier:

NCT00322218

EudraCT Number:

2005-001727-11

EU CT Number:

Not Available
Zevalin high risk aggressive NHL

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

60 Years
  • -

  • -

Trial summary

Enrollment Goal
68
Trial Dates
May 2006 - December 2008
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Zevalin (Ibritumomab tiuxetan, BAY86-5128)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Terminated
Ottawa Hospital-General CampusOttawa, K1H 8L6, Canada
Completed
Cross Cancer InstituteEdmonton, T6G 1Z2, Canada
Completed
Sunnybrook Health Sciences CentreToronto, M4N 3M5, Canada
Completed
CHUM - Hopital Notre-DameMontreal, H2L 4M1, Canada
Terminated
Medizinische Universität GrazGraz, 8036, Austria
Completed
Universitätsklinikum InnsbruckInnsbruck, 6020, Austria
Terminated
UZ Leuven GasthuisbergLeuven, 3000, Belgium
Completed
UZ GentGent, 9000, Belgium
Terminated
AZ St-Jan Brugge Oostende AVBrugge, 8000, Belgium
Completed
HUS, Meilahden sairaalaHelsinki, 00029, Finland
Completed
Oulun yliopistollinen sairaalaOulu, 90029, Finland
Completed
Hopital Claude-Huriez CHRULille Cedex, 59037, France
Completed
Hopital DupuytrenLimoges, 87042, France
Completed
Centre Léon BérardLyon, 69003, France
Completed
Centre Hospitalier Regional Henri MondorCreteil, 94010, France
Completed
Hôpital de la Pitié-Salpétrière - ParisParis, 75013, France
Completed
Centre hospitalier du BocageDijon, 21034, France
Terminated
C. H. U. Hopital PurpanToulouse, 31059, France
Completed
Johannes-Gutenberg-Universität MainzMainz, 55131, Germany
Completed
Städtisches Klinikum Karlsruhe gGmbHKarlsruhe, 76133, Germany
Terminated
Universität Rostock - Medizinische FakultätRostock, 18057, Germany
Terminated
Klinikum der Friedrich-Schiller-Universität JenaJena, 07743, Germany
Terminated
Klinikum der Universität WürzburgWürzburg, 97080, Germany
Completed
Klinikum Chemnitz gGmbHChemnitz, 09113, Germany
Terminated
Leicester Royal InfirmaryLeicester, LE2 7LX, United Kingdom
Terminated
St Bartholomews HospitalLondon, EC1A 7BE, United Kingdom
Terminated
Royal Marsden NHS Trust (Surrey)Surrey, SM2 5PT, United Kingdom
Completed
St James's HospitalDublin, Ireland
Terminated
Mater Misericordiae University HospitalDublin, DUBLIN 7, Ireland
Terminated
Galway University HospitalGalway, Ireland
Terminated
Research Ethics CommitteeDublin 7, Ireland
Completed
Policlinico S.Orsola-MalpighiBologna, 40138, Italy
Completed
IRCCS Ist Europeo OncologiaMilano, 20141, Italy
Terminated
Ospedale Santa ChiaraPisa, 56126, Italy
Completed
Ospedale Niguarda Ca'GrandaMilano, 20122, Italy
Completed
Ospedale Le MolinetteTorino, 10126, Italy
Completed
Ospedale SilvestriniPerugia, 06122, Italy
Completed
Uniwersyteckie Centrum KliniczneGdansk, 80-952, Poland
Terminated
SP Szpital Kliniczny nr 2Poznan, 60-569, Poland
Completed
Centrum Onkologii - Instytut im. M.Sklodowskiej-CurieWarszawa, 02-781, Poland
Completed
Szpital Uniwersytecki w KrakowieKrakow, 31-501, Poland
Completed
Instituto Portugues de Oncologia de Francisco GentilLisboa, 1070-213, Portugal
Terminated
Hospitais da Universidade de CoimbraCoimbra, 3000-076, Portugal
Completed
Centro Hospitalar de Lisboa Norte - Hospital Santa MariaLisboa, 1649-035, Portugal
Completed
Instituto Portugues de Oncologia de Francisco GentilPorto, 4200-072, Portugal
Completed
Hospital Clínico de SalamancaSalamanca, 37007, Spain
Terminated
Hospital General Universitario Gregorio MarañónMadrid, 28007, Spain
Terminated
Clinica Universitaria de NavarraPamplona, 31008, Spain
Terminated
Hospital Universitario Virgen del RocíoSevilla, 41013, Spain
Terminated
Hospital Universitario "La Paz"Madrid, 28046, Spain
Completed
Norrlands UniversitetssjukhusUmea, 901 85, Sweden
Completed
Universitetssjukhuset MASMalmo, 20502, Sweden
Completed
Uddevalla sjukhusUddevalla, 451 80, Sweden
Terminated
Inselspital BernBern, 3010, Switzerland
Completed
Kantonsspital St. GallenSt. Gallen, 9007, Switzerland
Completed
National Institute of OncologyBudapest, 1122, Hungary
Completed
University of Debrecen Medical&Health Science CenterDebrecen, 4032, Hungary
Terminated
Szegedi Tudomanyegyetem, SZAOTESzeged, 6720, Hungary
Terminated
University of SemmelweisBudapest, 1083, Hungary
Completed
Seoul National University HospitalSeoul, 110-744, Korea, Republic Of
Completed
Severance Hospital, Yonsei University College of MedicineSeoul, 120-752, Korea, Republic Of
Completed
National Cancer CentreSingapore, 169610, Singapore
Completed
Siriraj Hospital, MahidolBangkok, 10700, Thailand
Terminated
Gulfcoast Oncology AssociatesSt. Petersburg, 33705, United States
Terminated
Joliet Oncology Hematology Associates, Ltd.Joliet, 60435, United States
Completed
Park Nicollet Clinic - St. Louis ParkSt. Louis Park, 55416, United States
Terminated
Tower Hematology/Oncology Medical GroupBeverly Hills, 90211, United States
Terminated
North Shore Hematology and Oncology AssociatesEast Setauket, 11733, United States
Terminated
Comprehensive Blood and Cancer CenterBakersfield, 93309, United States
Terminated
North Idaho Cancer CenterCoeur d'Alene, 83814, United States
Terminated
Virginia Oncology AssociatesNorfolk, 23502, United States
Terminated
Alta Bates Comprehensive Cancer CenterBerkeley, 94704, United States
Terminated
Mayo Clinic - RochesterRochester, 55905, United States
Terminated
Kansas City Cancer Centers, LLCOverland Park, 66210, United States
Terminated
Oncology Services of AberdeenAberdeen, 57401, United States
Terminated
Kaiser Permanente San Diego Medical CenterSan Diego, 92120, United States
Terminated
Kaiser Permanente Vallejo Medical CenterVallejo, 94589, United States
Terminated
United States
Terminated
Beth Israel Deaconess Medical CenterBoston, 02215, United States

Trial design

A phase III, open-label, prospective, two-armed, multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) study regimen versus observation in patients with diffuse large B-cell lymphoma who are in complete remission after first-line CHOP-rituximab (CHOP-R) therapy
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.